8:37 AM ET
8-K
Divestiture
Myriad Genetics Divestiture to Laboratory Corporation of America for $210M
Myriad Genetics has entered into a definitive agreement to sell its prenatal health testing business, including the Foresight, Prequel, and SneakPeek tests, to Labcorp for $210 million in cash. The divestiture is part of a strategic review to focus on the company's cancer care continuum and is expected to close by early 2027.
- Value
- $210M
- Counterparty
- Laboratory Corporation of America